Navigation Links
Watchful Waiting Effective for Low Risk Prostate Cancer

"Watchful Waiting" may be more appropriate in men with low-risk prostate cancer than the common method of treating with surgery or radiation therapy, according to a research// team at the University of Michigan in Ann Arbor.

The results of the study conducted by lead researcher Dr. John T. Wei and his associates have been published in the Journal of the National Cancer Institute. Their studies have revealed that watchful waiting or "expectant management" which includes regular checkups to see if treatment is necessary is a better option for men with early-stage prostate cancer.

The study states, "Just as a failure to treat a potentially lethal prostate cancer is generally considered inappropriate from a quality-of-care perspective. Aggressive treatment of indolent cancers (i.e., overtreatment) may also reflect suboptimal care in that it confers risk to patients and increases costs without providing health benefits."

The team led by Wei evaluated information in national databases and identified 71,602 men diagnosed with localized or regional cancer of the prostate between January 2000 and December 2002.

They categorized the risk to the patients from their cancers according to how well differentiated the tumor was rather than spread-out with indistinct boundaries.

The "lower risk" prostate cancer group were said to be men of any age diagnosed with well-differentiated tumors or men 70 years or older at diagnosis with moderately differentiated tumors."

The study revealed that about a third of subjects were classified as having lower risk cancer. Although good candidates for a watchful waiting approach, 55 percent underwent immediate treatment with 45 percent of them having received radiation therapy and 10 percent having undergone surgical removal of the prostate both of which could be considered as over treatment.

According to Wei's team "initial expectant management need not be a perma
'"/>




Page: 1 2

Related medicine news :

1. New Study To Determine "Watchful Waiting" Period For Prostate Cancer
2. Watchful Eyes Ensures Honesty
3. Mobile Operating Theater to Cut Waiting Times
4. NHS To Achieve Waiting Figure Target By 2008
5. Gynecologist Solving SuDoKu, While Waiting For Next Patient
6. New Study To Determine "Watchful Waiting" Period For Prostate Cancer
7. 800 People On US Waiting List for AIDS Drugs
8. Funds Pumped In To Reduce Waiting List of Priority Patients
9. UK Patients Seek Fertility Treatment Abroad Due To The Long Waiting List
10. Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery
11. Long Patient Waiting Times Force NHS Patients To Seek Treatment Abroad
Post Your Comments:
(Date:5/16/2008)...edicine is in a precipitous decline, David C. Dale...hysicians (ACP), today joined with leading repres...ll for comprehensive reforms to attract, recruit a...e physicians. , During a panel discussion of th...Dale and other panelists spoke about the challenge...
(Date:5/16/2008)...wswire/- "Huh, what did you,say?" is a phrase bein...hildren. More than 30 million Americans, that is 1...nd the numbers are growing at a dramatic rate.,Thi...me form of hearing,loss. An effort to bring more a...at led Kathlyn Maguire, who has profound hearing l...
(Date:5/16/2008)...Million for Life-threatening,Disease, BETHESDA, M...early,every state will raise funds for cystic fibr...ting in GREAT STRIDES, the largest national CF,fun... today., May is National Cystic Fibrosis Awarenes...etic disease that causes fatal lung infections and...
(Date:5/16/2008)...10,000 Sensual O Condom Packs Donation Marks the ... LOS ANGELES, May 16 /PRNewswire/ -- On Saturday, ...wn best for his hit song "Everybody in the Club,Ge...Institute (UHI) with,10,000 Sensual O Vibrating Co...ng made to promote the launch of the Association f...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Everybody in the Club Scream O! 2
... interesting study it was found that older women s...felong viral infection- acquired early in life) we...g frail than those who did not have the infection.... Geriatrics Society. This is the first time an ass...
...major breakthrough the British scientists have rep...n cells from stem cells. Professor Harry Moore fro...id that "the research meant it might ultimately be... use in assisted conception treatments". It should...
...ons prefer complete revascularization technique to...bypass surgery. The procedure is said to increase ... surgery. Surgeons from Cedars-Sinai Medical Cente...d blockages in multiple of coronary arteries have ...
...ren who are being diagnosed for diabetes type 2 ma...ric illness at the onset of the disease. A study d...of Philadelphia have shown that among the children...type 2 disease, two out of five of them have showe...
Other Medicine News:
(Date:5/16/2008)...s Potential Biomarkers -- for Lung Cancer Diagnosi...With Cancer of Unknown Primary ...fy Cancer Types With High Sensitivity and, Speci...ment of Cancer Results of microRNA Signature to I...racy Exceeding 90% and Specificity of 99%, REHOVO...
(Date:5/15/2008)...KE, N.J., May 15 /- Eisai Corporation...m 16 clinical data abstracts about,compounds in th...nd,preclinical oncology research have been accepte...he American Society of Clinical Oncology (ASCO),t...., A wide variety of abstracts on Eisai marketed ...
(Date:5/15/2008)...Presented at ASCO Showed Acceptable Tolerability P...and 4 Neuropathy, WOODCLIFF LAKE, N.J., May 15 /P... agent eribulin mesylate (E7389) demonstrated acti...ith locally advanced or metastatic,breast cancer, ...inical,trial. The study also suggests that eribuli...
(Date:5/15/2008)... N.J., May 15 /- Sanofi-ave... that findings from the,landmark ATHENA study show...r the treatment of patients with atrial fibrillati...vascular hospitalizations or death from any,cause ... meeting the study,primary endpoint. The ATHENA re...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 1Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 1Precancerous Breast Lesions Cause Unnecessary Worry 11716 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 3Precancerous Breast Lesions Cause Unnecessary Worry 11716 4Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 1Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 2Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 3Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 1Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 2
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std.
Cholesterol/HDL with 200 tests.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl.
Medicine Products: